Keytruda (pembrolizumab)

pCPA File Number: 22073
Negotiation Status:
Concluded with an LOI
Indication(s):
for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection
Sponsor/Manufacturer:
Merck Canada
CADTH Project Number:
PC0286
pCPA Engagement Letter Issued:
Negotiation Process Concluded: